Connect Biopharma (CNTB) Competitors $1.52 +0.37 (+32.17%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.52 -0.01 (-0.33%) As of 07/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTB vs. PRQR, NBTX, YMAB, IMAB, CRDF, INBX, MDWD, SOPH, MNPR, and SCPHShould you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include ProQR Therapeutics (PRQR), Nanobiotix (NBTX), Y-mAbs Therapeutics (YMAB), I-Mab (IMAB), Cardiff Oncology (CRDF), Inhibrx Biosciences (INBX), MediWound (MDWD), SOPHiA GENETICS (SOPH), Monopar Therapeutics (MNPR), and scPharmaceuticals (SCPH). These companies are all part of the "pharmaceutical products" industry. Connect Biopharma vs. Its Competitors ProQR Therapeutics Nanobiotix Y-mAbs Therapeutics I-Mab Cardiff Oncology Inhibrx Biosciences MediWound SOPHiA GENETICS Monopar Therapeutics scPharmaceuticals ProQR Therapeutics (NASDAQ:PRQR) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership. Which has stronger earnings & valuation, PRQR or CNTB? Connect Biopharma has higher revenue and earnings than ProQR Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProQR Therapeutics$20.46M11.93-$30.04M-$0.35-6.63Connect Biopharma$26.03M3.24-$15.63MN/AN/A Which has more volatility and risk, PRQR or CNTB? ProQR Therapeutics has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.2, meaning that its share price is 120% less volatile than the S&P 500. Do insiders & institutionals hold more shares of PRQR or CNTB? 32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend PRQR or CNTB? ProQR Therapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 244.83%. Connect Biopharma has a consensus target price of $7.00, suggesting a potential upside of 360.53%. Given Connect Biopharma's higher probable upside, analysts plainly believe Connect Biopharma is more favorable than ProQR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Connect Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor PRQR or CNTB? In the previous week, Connect Biopharma had 2 more articles in the media than ProQR Therapeutics. MarketBeat recorded 5 mentions for Connect Biopharma and 3 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 0.99 beat Connect Biopharma's score of 0.62 indicating that ProQR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Connect Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is PRQR or CNTB more profitable? Connect Biopharma has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -157.04%. Connect Biopharma's return on equity of 0.00% beat ProQR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ProQR Therapeutics-157.04% -53.49% -22.07% Connect Biopharma N/A N/A N/A SummaryConnect Biopharma beats ProQR Therapeutics on 9 of the 15 factors compared between the two stocks. Get Connect Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTB vs. The Competition Export to ExcelMetricConnect BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$63.90M$2.99B$5.60B$9.11BDividend YieldN/A2.39%5.24%4.02%P/E RatioN/A20.5827.9620.25Price / Sales3.24291.28430.5799.61Price / CashN/A42.8637.4658.16Price / Book0.917.638.045.49Net Income-$15.63M-$55.05M$3.18B$250.27M7 Day Performance33.92%8.39%3.63%4.75%1 Month Performance78.82%5.35%4.04%7.64%1 Year Performance21.60%1.95%29.56%16.34% Connect Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTBConnect Biopharma3.1599 of 5 stars$1.52+32.2%$7.00+360.5%+22.6%$63.90M$26.03M0.00110News CoverageGap UpHigh Trading VolumePRQRProQR Therapeutics2.576 of 5 stars$2.04flat$8.00+292.2%+34.1%$214.63M$20.46M-5.83180Analyst ForecastNBTXNanobiotix2.7934 of 5 stars$4.73+4.4%$8.00+69.1%-7.1%$213.34M$39.18M0.00100Positive NewsGap UpYMABY-mAbs Therapeutics4.0131 of 5 stars$4.51-4.0%$15.60+245.9%-63.9%$212.83M$87.68M-7.05150IMABI-Mab2.9205 of 5 stars$2.42-5.8%$6.00+147.9%+34.8%$209.87M$3.89M0.00380Analyst ForecastGap UpCRDFCardiff Oncology1.2792 of 5 stars$3.15flat$9.88+213.5%+64.8%$209.56M$680K-3.4220Analyst ForecastINBXInhibrx Biosciences2.5614 of 5 stars$14.27-1.1%N/A+64.3%$208.89M$200K0.12166News CoverageMDWDMediWound1.8475 of 5 stars$19.37+0.6%$31.80+64.2%-0.3%$208.16M$20.22M-9.2780SOPHSOPHiA GENETICS2.7371 of 5 stars$3.10+0.3%$7.00+125.8%-25.9%$206.06M$65.17M-3.10520Positive NewsMNPRMonopar Therapeutics2.0231 of 5 stars$35.78+6.5%$56.50+57.9%+924.0%$205.47MN/A-10.2810Analyst RevisionSCPHscPharmaceuticals4.5026 of 5 stars$3.81-1.6%$14.00+267.5%-4.8%$204.30M$36.33M-1.9930Positive News Related Companies and Tools Related Companies PRQR Competitors NBTX Competitors YMAB Competitors IMAB Competitors CRDF Competitors INBX Competitors MDWD Competitors SOPH Competitors MNPR Competitors SCPH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTB) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Connect Biopharma Holdings Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Connect Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CNTB Stock Alerts